Durchbruch in der Entwicklung eines schnell verfügbaren, effektiven Wirkstoffs gegen das Coronavirus
Aptamer BC 007 von Berlin Cures ist auf dem Weg in klinische Phase-II/III-Studie
Berlin (pts008/06.07.2020/10:00) - Forscher des Life-Science-Unternehmens Berlin Cures haben kürzlich in Tests nachgewiesen, dass das von ihnen entwickelte Aptamer BC 007 in der Lage ist, das pandemische Co...
Read More
NEWS: Berlin Cures plans clinical study with BC 007 for Covid-19
Berlin Cures to Evaluate BC 007, an Aptamer, in Patients for the Treatment of COVID-19
Phase II/III clinical trial is scheduled to start in the second half of 2020
Berlin, Germany – 24 June 2020 – Berlin Cures Holding AG, a biotech company developing aptamers for autoimmune diseases, today announces that it is evaluating BC 007, a β1-adrenoceptor autoantibody (β1-AAb) neutralizing ssDN...
Read More
New Paper: Results of the Phase 1 study with BC 007
A new paper is out summarizing the Phase 1 study with BC 007.
Read the full text HERE
home
Read More
New Paper: The DNA-Based Drug BC 007 neutralizes agonistically acting autoantibodies directed against G protein–coupled receptors
Müller et al. (2019) The DNA-Based Drug BC 007 Neutralizes Agonistically Acting Autoantibodies Directed Against G Protein–Coupled Receptors -Successful Mode of Action Demonstrated in Clinical Phase 1 Trial. Chemistry Today March/April 37(2), 65-67
Read the abstract here and read full text article here
download full text article
Read More
NEWS: Berlin Cures announces start of Phase 2a for its DNA-based neutralizer of ß1-adrenoceptor autoantibodies
Read full text here:
https://www.teknoscienze.com/berlin-cures-announces-start-of-phase-iia-for-its-dna-based-neutralizer-of-β1-adrenoceptor-autoantibodies/
Read More
NEWS: Berlin Cures’ Steering Committee is Assembled to Facilitate the Design and Implementation of Phase 2 Study of BC 007
ZUG, Switzerland, Dec. 6, 2018 /PRNewswire/ -- Swiss drug developer Berlin Cures Holding AG today announced the establishment of a steering committee of renowned cardiologists focused on ensuring expert input during the design and implementation of the Phase 2 study of BC 007 for the treatment of dilated cardiomyopathy.
"By convening an international team of experts to provide guidance around t...
Read More
New paper: Characterization of Aptamer BC 007 Substance and Product Using Circular Dichroism and Nuclear Magnetic Resonance Spectroscopy
https://www.sciencedirect.com/science/article/pii/S0022354918302053
Read More
NEWS: Berlin Cures Announces Successful Completion of Phase 1 Study of BC 007 for the Treatment of Cardiomyopathy
ZUG, Switzerland, Aug. 22, 2018 /PRNewswire/ -- Drug developer Berlin Cures today announced the successful completion of its Phase 1 study of BC 007, a DNA-based aptamer compound that binds to and eliminates functional pathogenic autoantibodies for the treatment of cardiomyopathy.
"The safety profile of BC 007 continues to be excellent," said Dr. Johannes Müller, founder and president of the Bo...
Read More
NEWS: Berlin Cures Announces Formation of Scientific Advisory Board
Berlin Cures Announces Formation of Scientific Advisory Board
Inaugural Members Include Leading Experts in Cardiology and Autoimmunity
ZUG, Switzerland, May 23, 2018 /PRNewswire/ -- Drug developer Berlin Cures today announced the formation of a Scientific Advisory Board (SAB) and the appointment of its first two members, Prof. Beda M. Stadler and Prof. Wilhelm Vetter, to help advance the cli...
Read More
NEWS: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study
BC007 Eliminates Autoantibodies Linked to Disease in 80% of Patients
First Drug to Attack the Cause of Dilated Cardiomyopathy
ZUG, Switzerland, and BERLIN, Feb. 26, 2018 – The first drug designed to eliminate autoantibodies that are a major cause of heart failure and to treat heart failure symptoms was effective and well-tolerated in a Phase 1 clinical study, according to an oral presentatio...
Read More